RAYTWELSI — 2345810
Application number
2345810
Registration number
TMA1397682
Type(s)
Standard Characters
Category
Trademark
CIPO Status
REGISTERED
TM5 status
LIVE/REGISTRATION/Issued
and Active
The trademark application has been registered with the Office.
Filed
2024-08-26
Registered
2026-03-25
Registration Expiry Date
2036-03-25
Registered Owner
Eli Lilly and Company
Eli Lilly Corporate Center
Indianapolis, IN 46285
UNITED STATES OF AMERICA
Agent
BORDEN LADNER GERVAIS LLP
World Exchange Plaza
100 Queen Street, Suite 1300
Ottawa
ONTARIO K1P1J9
Documents
Index headings
- RAYTWELSI
Goods (Nice class & Statement)
- 5
- (1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone diseases and disorders and musculoskeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, eczema, acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, diabetes, dyslipidemia, endocrine diseases and disorders, namely, growth and thyroid disorders, diabetes and obesity, and hormonal diseases, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases, inflammatory muscle diseases and disorders and pharmaceutical preparations for the treatment of inflammation, namely anti-inflammatory preparations, pharmaceutical preparations for the treatment of kidney diseases and disorders, liver diseases and disorders, lupus, mental health disorders, metabolic diseases and disorders, namely, diabetes, gout, arthritis and anemia, obesity, hyperlipidemia, insulin resistance and metabolic syndrome, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, namely, Alzheimer's, Huntington's disease, cerebral palsy, brain injury, spinal cord injury, and seizure disorders, amyotrophic lateral sclerosis (ALS), encephalitis, meningitis, muscular dystrophy, myasthenia gravis, dystonia, epilepsy, seizures, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases.
Action History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2024-08-26 | ||
| Created | 2024-08-26 | ||
| Formalized | 2024-08-26 | ||
| Pre-Assessment Letter Sent | 2024-09-05 | Goods or Services Not Acceptable | |
| Search Recorded | 2025-03-12 | ||
| Examiner's First Report | 2025-03-12 | 2025-09-12 | |
| Correspondence Created | 2025-09-15 | 2026-03-15 | |
| Approved | 2025-10-22 | APPROVED BY PROGRAM EX200M1 | |
| Approval Notice Sent | 2025-10-22 | APPROVED BY PROGRAM EX200M1 | |
| Advertised | 2026-01-07 | Vol.73 Issue 3715 | |
| Registration Pending | 2026-03-25 | ||
| Registered | 2026-03-25 | 2036-03-25 |